Aurinia Pharmaceuticals Inc Stock News

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today annou

One day after moving higher in the market, Aurinia Pharmaceuticals (NASDAQ: AUPH) stock was deep in the loss column on Thursday. Optimism flowing from good news the previous day was erased by the Can

Aurinia Prices US$200 Million Public Offering of Common Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today annou

What happened? Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by 10.4% as of 11:15 a.m. EDT on Wednesday, after the company announced that the U.S. Food and Drug Administration (FDA) accepted

Scaling The Peaks(Biotech Stocks Hitting 52-week Highs July 21) * ABIOMED, Inc. (NASDAQ: ABMD) * Assembly Biosciences Inc (NASDAQ: ASMB) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Beigene Ltd (NAS

Shares in Aurinia Pharma (AUPH) surged 9% in Tuesday’s extended trading after the U.S. Food and Drug Administration (FDA) accepted the filing of its New Drug Application (NDA) for voclosporin, a pot

Aurinia Announces U.S. FDA Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Guru ups bet in biotech focused on ear-related disorders Continue reading...

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin

Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today

Canadian biopharma Aurinia Pharmaceuticals (NASDAQ: AUPH) is undergoing a transformation. The company is embarking on a rare opportunity to deliver the first U.S. Food and Drug Administration (FDA) a

Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announc

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen